美国国家公共电台 NPR Scientists Race To Improve 'Living Drugs' To Fight Cancer

NOEL KING, HOST:

There's been a really exciting advance in the war on cancer with the help of what scientists are calling living drugs. They're made by genetically 1 modifying patients' own immune system cells. And today NPR's health correspondent Rob Stein brings us the story of how doctors are trying to save terminally ill patients with these living drugs.

ANDREA GROSS: Hi, Aaron.

KATIE BARNETT: Good morning. How you doing?

AARON REID: I'm good.

ROB STEIN, BYLINE 2: Aaron Reid is lying in a hospital bed at the National Institutes of Health when doctors Andrea Gross and Katie Barnett stopped by for their daily check-in.

BARNETT: How was your night?

REID: Good.

BARNETT: Any issues?

REID: No.

BARNETT: Feeling good?

REID: Uh-huh.

BARNETT: All right.

STEIN: Aaron is from Lucedale, Miss. He just turned 20. He's been fighting leukemia since he was 9.

GROSS: Take a deep breath in - and out. In. Out. OK, good.

STEIN: Over the years, Aaron's been through two grueling rounds of chemo and radiation, a bone marrow 3 transplant and more. But the leukemia just keeps coming back. This time, the cancer's everywhere. He can feel the pain on his bones all over his body.

REID: I had to take some pain meds earlier.

GROSS: So we do hope that that's going to get better with treatment.

STEIN: Aaron's pretty much run out of options. So he's here today to try another treatment, an experimental treatment that could be his last hope.

BARNETT: Your numbers today, they all look good. The plan is to go ahead and do the cell infusion 4 today. Any questions right now?

REID: No.

BARNETT: All right.

GROSS: The big plan for the day - get the cells.

REID: Yeah.

GROSS: All right.

STEIN: The cells are the treatment, his own immune system cells. The doctors pulled them out of his blood and genetically modified them in the lab.

REID: I think it's amazing that they can find a way to use someone's own - you know, take out their own cells, teach it to do something and then put it back in them and - to be able to heal them. I think that's amazing.

(SOUNDBITE OF ELEVATOR RECORDING)

AUTOMATED 5 VOICE: Third floor - going down.

STEIN: While Aaron waits for his cells, I head downstairs to find out more about how these living drugs work.

NIRALI SHAH: Hi.

STEIN: Hi, Dr. Shah. It's Rob Stein from NPR.

SHAH: Nice to meet you.

STEIN: Nice to meet you, too.

Dr. Nirali Shah is in charge of Aaron's study. She says scientists genetically engineer the immune cells to recognize and attack unique targets on the cancer cells.

SHAH: So what we are doing is we are educating them to say these things don't belong. You need to get rid of them. Yes, I know that they started in the body, but they're not supposed to be there. You need to attack.

STEIN: But that's not all. Once the cells are back in a patient's body, they take on a life of their own.

SHAH: It's an army that multiplies when it has a bigger job to do.

STEIN: Oh, wow. So they - you put them back in the body. And they look around and say, oh, it's a lot of these guys in here. We need more of ourselves. And they reproduce and kind of swarm 6 the cancer?

SHAH: That's exactly right. It's a living drug. It multiplies in the body.

STEIN: These living drugs are already saving the lives of kids and younger adults who would otherwise die of leukemia and adults who would otherwise die from lymphoma.

SHAH: This is incredible. It's been a phenomenal success.

STEIN: But these living drugs are far from perfect. They're really expensive, can be dangerous. No one knows if they work on the most common tumors, like breast cancer, lung cancer, prostate cancer. And even for leukemia and lymphoma, the cancer often comes back. That's what happened to Aaron.

SHAH: Leukemia's smart. Our therapy is really good, but the leukemia has found a way to outsmart our really, really exciting therapy. And so we have to find a way to attack it differently.

STEIN: So scientists around the world are doing hundreds of studies to try to make better living drugs - more affordable 7, safer, more powerful. Shah's team is testing an approach that genetically modified Aaron's cells to go after two targets unique to his leukemia instead of just one.

SHAH: One of my patients called it the one-two punch.

STEIN: So it's sort of like a double whammy.

SHAH: That's exactly right. Maybe we can really get at the leukemia and prevent one of those leukemia cells from outsmarting the immune therapy and get rid of each and every single one so that there's no chance for even one of those little buggers from escaping and coming back at a later time.

STEIN: And that's why Aaron Reid is here today, to try this new double-whammy living drug.

(SOUNDBITE OF STORAGE TANK OPENING)

STEIN: In a lab at the hospital, technicians pull open a huge metal tank and slide out Aaron's cells.

SHAH: Patient - Reid, Aaron Michael - seven, seven, eight, eight, three, two, zero.

STEIN: After testing, checking and triple-checking the cells, they fill a huge syringe with 17 million of Aaron's tailor-made living drugs cells and rush them to Aaron's room.

UNIDENTIFIED TECHNICIAN: All right. So where's this going, 3 Northeast?

SHAH: Three Northeast.

UNIDENTIFIED TECHNICIAN: All right. Cool.

SHAH: I'm going to give the nurse a heads-up that you are coming.

UNIDENTIFIED TECHNICIAN: All righty.

UNIDENTIFIED NURSE #1: Hi. Ready?

REID: Yep.

UNIDENTIFIED NURSE #1: Good.

STEIN: Once the cells arrive in Aaron's room, the nurses confirm one more time that they've got the right cells for the right patient.

UNIDENTIFIED NURSE #2: So I have Mr. Aaron Michael Reid.

UNIDENTIFIED NURSE #1: So state your name.

REID: Aaron Reid.

STEIN: While they take his temperature and check his blood pressure, Dr. Shah makes sure Aaron's ready.

SHAH: I just wanted to check in, make sure that there are no additional questions.

REID: No, pretty much answered anything I ever had. Let's get it over with.

STEIN: The nurse leans over Aaron's bed holding the huge syringe with his cells and inserts the tip into a tube in his chest.

UNIDENTIFIED NURSE #2: I'm infusing the cells right now. These are the cells.

STEIN: As the cells slowly drip into his body, the nurses watch Aaron's vital signs to make sure he's not having a bad reaction.

UNIDENTIFIED NURSE #2: Keep an eye on the machine and keep an eye on the face. Once the face starts to get flushed, you know that something is happening. But then that will also be indicated on their vital signs monitor. So...

STEIN: But right now?

UNIDENTIFIED NURSE #2: Everything looks perfect right now.

STEIN: After about five minutes, it's done.

UNIDENTIFIED NURSE #2: It's completed. Feeling OK?

REID: Yeah.

STEIN: Aaron's doctors will now watch him closely, looking for the first signs the treatment is starting to work. Within a few weeks, Dr. Shah says his genetically engineered cells should kick into high gear and explode like a storm.

SHAH: The first hint of a fever and achiness and things like that, we get really excited because it means a storm is coming. But along with the storm, it means that the cells are getting activated 8, and they're going to start doing their job.

STEIN: In most cases, it's like the worst flu you've ever had. It can get really bad, though, even life-threatening. But most patients get through it.

How are you feeling right now?

REID: Still pretty excited - this is all kind of really exciting stuff. You know, don't know what's going to happen. And hopefully, it works.

STEIN: The room gets quiet for a moment. Dr. Shah whispers to me as she gets ready to head back to her office.

SHAH: So now we wait.

STEIN: Now we wait.

Rob Stein, NPR News, Bethesda, Md.

(SOUNDBITE OF DIAMIN'S "PERCEPTIONS")